Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Apolo Discusses Managing Immune-Related Toxicities in Bladder Cancer

December 14th 2017

Andrea Apolo, MD, discusses the management of immune-related adverse events in the treatment of bladder cancer.

Active Surveillance Underused in Prostate Cancer Patients Who Want to Preserve Sexual Function

December 13th 2017

In results from the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study, 52.6% said that preserving sexual function was “very important,” but only 43.4% were assigned to active surveillance.

Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

December 12th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC

December 12th 2017

In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1

Dr. McKay Discusses Immunotherapy Trials in RCC

December 12th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.

Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC

December 8th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

Immunotherapy Combinations Poised to Shift Standard of Care in RCC

December 7th 2017

Hans Hammers, MD, PhD, discusses the game-changing combination of nivolumab and ipilimumab and highlighted other combinations that have potential in the treatment of patients with renal cell carcinoma.

Dr. Grivas on the Next Steps for Immunotherapy in Bladder Cancer

December 7th 2017

Petros Grivas, MD, PhD, medical oncologist, Cleveland Clinic, discusses next steps for immunotherapy for the treatment of patients with bladder cancer.

Dr. Armstrong on Sipuleucel-T in Prostate Cancer

December 7th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Hammers on the CheckMate-214 Study for RCC

December 6th 2017

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).

Dr. Jonasch on Sequencing Challenges in RCC

December 5th 2017

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).

Neoadjuvant Chemotherapy Significantly Improves OS for Low-Risk, Basal Bladder Cancer

December 2nd 2017

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC

December 1st 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer

December 1st 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC

December 1st 2017

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

Dr. Sonpavde Discusses Current Clinical Trials in Penile Cancer

December 1st 2017

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses current clinical trials in penile cancer.

Dr. Hammers Discusses Combining IDO and PD-1 Inhibitors in RCC

December 1st 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.

Dr. Harrison on Choosing Frontline Treatment for RCC

December 1st 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Plimack Recaps 2017 Immunotherapy Approvals in Bladder Cancer

December 1st 2017

It has been a landmark year for immunotherapy in bladder cancer with the approval of 5 checkpoint inhibitors across first and second line.

Immunotherapy Combinations on the Rise for RCC

November 30th 2017

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.